CU24428B1 - Derivados de quinolizinona como inhibidores de pi3k - Google Patents

Derivados de quinolizinona como inhibidores de pi3k

Info

Publication number
CU24428B1
CU24428B1 CU2016000195A CU20160195A CU24428B1 CU 24428 B1 CU24428 B1 CU 24428B1 CU 2016000195 A CU2016000195 A CU 2016000195A CU 20160195 A CU20160195 A CU 20160195A CU 24428 B1 CU24428 B1 CU 24428B1
Authority
CU
Cuba
Prior art keywords
pi3k inhibitors
sup
quinolizinone derivatives
quinolizinone
derivatives
Prior art date
Application number
CU2016000195A
Other languages
English (en)
Other versions
CU20160195A7 (es
Inventor
Nirmal Kumar Jana
Rajender Kumar Kamboj
Sanjeev Anant Kulkarni
Dipak Raychand Lagad
Sachin Jaysing Mahangare
Venkata P Palle
Manojkumar Ramprasad Shukla
Anand Jagannath Tarage
Prashant Popatrao Vidhate
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53716533&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU24428(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of CU20160195A7 publication Critical patent/CU20160195A7/es
Publication of CU24428B1 publication Critical patent/CU24428B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

<p>Se divulgan compuestos de la fórmula I,</p> <p>ESPACIO PARA FÓRMULA</p> <p>sus formas tautoméricas, estereoisómeros, en donde R<sup>1</sup> y R<sup>4</sup> y n son como se define en la descripción. Dichos compuestos son útiles como inhibidores de la enzima PI3K.</p>
CU2016000195A 2014-07-04 2015-07-01 Derivados de quinolizinona como inhibidores de pi3k CU24428B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2182MU2014 2014-07-04
PCT/IB2015/054958 WO2016001855A1 (en) 2014-07-04 2015-07-01 Quinolizinone derivatives as pi3k inhibitors

Publications (2)

Publication Number Publication Date
CU20160195A7 CU20160195A7 (es) 2017-05-10
CU24428B1 true CU24428B1 (es) 2019-06-04

Family

ID=53716533

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2016000195A CU24428B1 (es) 2014-07-04 2015-07-01 Derivados de quinolizinona como inhibidores de pi3k

Country Status (25)

Country Link
US (1) US9944639B2 (es)
EP (1) EP3164400A1 (es)
JP (1) JP6291601B2 (es)
KR (1) KR20170082490A (es)
CN (1) CN106470996B (es)
AP (1) AP2016009661A0 (es)
AU (1) AU2015283671B2 (es)
BR (1) BR112017000132A2 (es)
CA (1) CA2954231A1 (es)
CL (1) CL2017000006A1 (es)
CO (1) CO2017000011A2 (es)
CR (1) CR20160600A (es)
CU (1) CU24428B1 (es)
EA (1) EA201692557A1 (es)
GE (2) GEAP201814408A (es)
HK (1) HK1232227A1 (es)
IL (1) IL249674B (es)
MA (1) MA40250A (es)
MX (1) MX2017000208A (es)
PE (1) PE20170640A1 (es)
PH (1) PH12017500007A1 (es)
SG (1) SG11201610770PA (es)
SV (1) SV2017005354A (es)
UA (1) UA115296C2 (es)
WO (1) WO2016001855A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017008867A2 (pt) * 2014-11-01 2017-12-26 Chongqing Fochon Pharmaceutical Co Ltd inibidores de proteína quinases
WO2017103825A1 (en) 2015-12-18 2017-06-22 Lupin Limited Quinolizinone derivatives as pi3k inhibitors
CA3083040A1 (en) 2018-01-20 2019-07-25 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
JP2021535907A (ja) * 2018-08-21 2021-12-23 南京明徳新薬研発有限公司 ピラゾロピリミジン誘導体及びそのｐｉ３ｋ抑制剤とする適用
BR112021020402A2 (pt) 2019-04-23 2021-12-07 Evotec Int Gmbh Moduladores da via de resposta ao estresse integrada
WO2021164789A1 (zh) * 2020-02-21 2021-08-26 南京明德新药研发有限公司 一种吡唑并嘧啶类化合物的晶型及其应用
CA3178569A1 (en) * 2020-05-16 2021-11-25 Zuwen ZHOU Compounds as protein kinase inhibitors
EP4363414A1 (en) * 2021-08-09 2024-05-08 Scorpion Therapeutics, Inc. Compounds that inhibit pi3k isoform alpha and methods for treating cancer

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
PT1278748E (pt) 2000-04-25 2011-03-31 Icos Corp Inibidores de delta 3-cinase humana de fosfatidilinositol
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
WO2005016349A1 (en) 2003-08-14 2005-02-24 Icos Corporation Methods of inhibiting leukocyte accumulation
WO2005016348A1 (en) 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
US20050239809A1 (en) 2004-01-08 2005-10-27 Watts Stephanie W Methods for treating and preventing hypertension and hypertension-related disorders
WO2005112935A1 (en) 2004-05-13 2005-12-01 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
JP2007537291A (ja) 2004-05-13 2007-12-20 イコス・コーポレイション ヒトホスファチジルイノシトール３−キナーゼデルタの阻害剤としてのキナゾリノン
JP2008500338A (ja) 2004-05-25 2008-01-10 イコス・コーポレイション 造血細胞の異常増殖を治療及び／又は予防する方法
WO2005120511A1 (en) 2004-06-04 2005-12-22 Icos Corporation Methods for treating mast cell disorders
WO2006089106A2 (en) 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
GB2453058A (en) 2006-04-04 2009-03-25 Univ California Kinase antagonists
US20100216820A1 (en) 2006-11-13 2010-08-26 White Stephen L Thienopyrimidiones for treatment of inflammatory disorders and cancers
WO2008118454A2 (en) 2007-03-23 2008-10-02 Amgen Inc. Derivatives of quinoline or benzopyrazine and their uses for the treatment of (inter alia) inflammatory diseases, autoimmune diseases or various kinds of cancer
PL2139882T3 (pl) 2007-03-23 2014-05-30 Amgen Inc 3-podstawione pochodne chinoliny lub chinoksaliny i ich zastosowanie jako inhibitorów 3-kinazy fosfatydyloinozytolu (pi3k)
MX2009009968A (es) 2007-03-23 2009-10-08 Amgen Inc Compuestos heterociclicos y sus usos.
JP2011503193A (ja) 2007-11-13 2011-01-27 アイコス、コーポレーション ヒトホスファチジルイノシトール３−キナーゼδの阻害剤
AU2009204487C1 (en) 2008-01-04 2014-10-16 Intellikine, Llc Certain chemical entities, compositions and methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP2346508B1 (en) 2008-09-26 2016-08-24 Intellikine, LLC Heterocyclic kinase inhibitors
KR20120002995A (ko) 2009-03-24 2012-01-09 길리아드 칼리스토가 엘엘씨 ２―퓨리닐―３―톨릴―퀴나졸리논 유도체의 회전장애 이성질체 및 사용 방법
PT2421536E (pt) 2009-04-20 2015-10-20 Gilead Calistoga Llc Métodos de tratamento para tumores sólidos
CA2760791C (en) 2009-05-07 2017-06-20 Intellikine, Inc. Heterocyclic compounds and uses thereof
MX2011013901A (es) * 2009-06-25 2012-05-08 Amgen Inc Derivados de 4h-pirido [1,2-a] pirimidin-4-ona como inhibidores de pi3k.
BR112012000660A2 (pt) 2009-06-25 2016-11-16 Amgen Inc compostos heterociclos e seus usos
BRPI1016150A2 (pt) 2009-06-25 2016-04-19 Amgen Inc compostos heterocíclicos e seus usos.
US8940752B2 (en) * 2009-06-29 2015-01-27 Incyte Corporation Pyrimidinones as PI3K inhibitors
MX2012000817A (es) 2009-07-21 2012-05-08 Gilead Calistoga Llc Tratamiento para desordenes del higado con inhibidores pi3k.
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
CA2779574C (en) 2009-11-05 2018-12-18 Rhizen Pharmaceuticals S.A. Novel kinase modulators
WO2011058112A1 (en) 2009-11-12 2011-05-19 Ucb Pharma S.A. Fused bicyclic pyrazole derivatives as kinase inhibitors
JP2013514989A (ja) 2009-12-18 2013-05-02 アムジエン・インコーポレーテツド 複素環式化合物およびその使用法
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
UY33304A (es) 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
AR081823A1 (es) 2010-04-14 2012-10-24 Incyte Corp DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd
ES2593256T3 (es) 2010-05-21 2016-12-07 Infinity Pharmaceuticals, Inc. Compuestos químicos, composiciones y métodos para las modulaciones de cinasas
EP2579878A1 (en) 2010-06-11 2013-04-17 Gilead Calistoga LLC Methods of treating hematological disorders with quinazolinone compounds in selected patients
CA2803619A1 (en) 2010-06-30 2012-01-05 Amgen Inc. Heterocycle compounds and their uses
WO2012003264A1 (en) 2010-06-30 2012-01-05 Amgen Inc. Nitrogen containing heterocyclic compounds as pik3 -delta inhibitors
JP2013530238A (ja) 2010-07-01 2013-07-25 アムジエン・インコーポレーテツド Ｐｉ３ｋ活性の阻害剤としての複素環化合物及びその使用
AU2011271460B2 (en) 2010-07-01 2014-02-06 Amgen Inc. Heterocyclic compounds and their use as inhibitors of P13K activity
US20130096134A1 (en) 2010-07-02 2013-04-18 Amgen Inc. Heterocyclic compounds and their uses
CA2812467A1 (en) 2010-09-24 2012-03-29 Gilead Calistoga Llc Atropisomers of pi3k-inhibiting compounds
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
MX2013005005A (es) 2010-11-04 2013-10-25 Amgen Inc Derivados de ciano-4,6-diaminopirimidina o 6-aminopurina como inhibidores de pi3k-delta.
US8901133B2 (en) 2010-11-10 2014-12-02 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2012068343A1 (en) 2010-11-17 2012-05-24 Amgen Inc. Quinoline derivatives as pik3 inhibitors
US20130267526A1 (en) 2010-12-23 2013-10-10 Amgen, Inc. Heterocyclic compounds and their uses
CN103648499B (zh) 2011-01-10 2017-02-15 无限药品股份有限公司 用于制备异喹啉酮的方法及异喹啉酮的固体形式
SG193337A1 (en) 2011-03-11 2013-10-30 Gilead Calistoga Llc Combination therapies for hematologic malignancies
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
UY34044A (es) * 2011-04-29 2012-11-30 Sanofi Sa Metodo de tratamiento contra el linfoma con inhibidores de piridopirimidinona de p13k/mtor
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
CN102838600A (zh) 2011-06-24 2012-12-26 山东亨利医药科技有限责任公司 苯基喹唑啉类PI3Kδ抑制剂
CN102838601A (zh) 2011-06-24 2012-12-26 山东亨利医药科技有限责任公司 选择性磷酰肌醇3-激酶δ抑制剂
AU2012284091B2 (en) 2011-07-19 2015-11-12 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
HK1198443A1 (en) 2011-07-19 2015-04-24 无限药品股份有限公司 Heterocyclic compounds and uses thereof
EP2751093A1 (en) 2011-08-29 2014-07-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN104024257A (zh) 2011-10-04 2014-09-03 吉利德卡利斯托加有限责任公司 Pi3k的新的喹喔啉抑制剂
US20130143902A1 (en) 2011-12-02 2013-06-06 Gilead Calistoga Llc Compositions and methods of treating a proliferative disease with a quinazolinone derivative
WO2013116562A1 (en) 2012-02-03 2013-08-08 Gilead Calistoga Llc Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
NZ627963A (en) 2012-03-13 2015-08-28 Respivert Ltd Dry powder pharmaceutical formulations for inhalation of a compound that inhibits pi3 kinase
PL2834231T3 (pl) 2012-04-04 2016-07-29 Amgen Inc Związki heterocykliczne i ich zastosowanie
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
BR112014033055B1 (pt) 2012-07-04 2023-01-31 Rhizen Pharmaceuticals S.A Compostos inibidores seletivos de delta pi3k, composição farmacêutica contendo os mesmos, e uso dos referidos compostos
WO2014015523A1 (en) 2012-07-27 2014-01-30 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods
CN104768952B (zh) 2012-08-08 2016-10-19 山东亨利医药科技有限责任公司 PI3Kδ抑制剂
AU2013302617A1 (en) 2012-08-14 2015-02-05 Gilead Calistoga Llc Combination therapies for treating cancer
WO2014060431A1 (en) 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
KR20150068953A (ko) 2012-10-16 2015-06-22 알미랄, 에스.에이. Ｐｉ３ｋ 저해제로서의 피롤로트리아지논 유도체
SI2914296T2 (sl) 2012-11-01 2022-01-31 Infinity Pharmaceuticals, Inc. Zdravljenje raznih vrst raka z uporabo modulatorjev izooblik PI3-kinaze
US20140120060A1 (en) 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors
US9029384B2 (en) 2012-12-21 2015-05-12 Gilead Calistoga, LLC. Phosphatidylinositol 3-kinase inhibitors
WO2014100765A1 (en) 2012-12-21 2014-06-26 Gilead Calistoga Llc Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
WO2014106800A2 (en) 2013-01-04 2014-07-10 Aurigene Discovery Technologies Limited Substituted 2-amino pyrimidine derivatives as kinase inhibitors
TW201446767A (zh) 2013-02-15 2014-12-16 Almirall Sa 作為磷脂肌醇3-激酶抑製劑之吡咯並三嗪衍生物
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
JO3279B1 (ar) 2013-03-15 2018-09-16 Respivert Ltd مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز
US9216985B2 (en) 2013-03-28 2015-12-22 Scifluor Life Sciences, Inc. 3-aryl-2-((arylamino)methyl)quinazolin-4-(3H)-ones
EA028319B1 (ru) 2013-06-14 2017-11-30 Джилид Калистога Ллс Ингибиторы фосфатидилинозитол-3-киназы
CN111153905A (zh) 2013-07-02 2020-05-15 理森制药股份公司 PI3K蛋白激酶抑制剂，特别是δ抑制剂和/或γ抑制剂
CN104447727B (zh) 2013-09-02 2018-04-27 广东东阳光药业有限公司 取代的氨基嘧啶类化合物及其使用方法和用途
MY184292A (en) 2013-09-22 2021-03-30 Sunshine Lake Pharma Co Ltd Substituted aminopyrimidine compounds and methods of use
US9775844B2 (en) 2014-03-19 2017-10-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
CN105130966B (zh) 2014-05-07 2019-05-24 广东东阳光药业有限公司 炔基化合物及其使用方法和用途
WO2015175579A1 (en) 2014-05-15 2015-11-19 Calitor Sciences, Llc Alkynyl compounds and methods of use
WO2015191752A1 (en) 2014-06-13 2015-12-17 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
US11021467B2 (en) 2014-06-13 2021-06-01 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
CA2952025A1 (en) 2014-06-13 2015-12-17 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
AR100975A1 (es) 2014-06-24 2016-11-16 Gilead Sciences Inc Inhibidores de fosfatidilinositol 3-quinasa
BR112017008867A2 (pt) 2014-11-01 2017-12-26 Chongqing Fochon Pharmaceutical Co Ltd inibidores de proteína quinases
CN105130984B (zh) 2015-09-23 2017-03-29 前湾医药科技（深圳）有限公司 一种咪唑并吡啶类化合物与在制备pi3k抑制剂中的应用

Also Published As

Publication number Publication date
CO2017000011A2 (es) 2017-04-10
SV2017005354A (es) 2018-10-05
MX2017000208A (es) 2017-05-01
PH12017500007A1 (en) 2017-05-15
HK1232227A1 (zh) 2018-01-05
SG11201610770PA (en) 2017-01-27
BR112017000132A2 (en) 2018-01-09
CA2954231A1 (en) 2016-01-07
CU20160195A7 (es) 2017-05-10
AU2015283671B2 (en) 2018-07-05
GEP20186934B (en) 2018-12-10
CN106470996B (zh) 2019-02-22
MA40250A (fr) 2017-05-10
CL2017000006A1 (es) 2017-06-02
GEAP201814408A (en) 2018-08-27
CR20160600A (es) 2017-03-07
CN106470996A (zh) 2017-03-01
AP2016009661A0 (en) 2016-12-31
PE20170640A1 (es) 2017-05-26
EP3164400A1 (en) 2017-05-10
UA115296C2 (uk) 2017-10-10
IL249674B (en) 2019-06-30
US20170137421A1 (en) 2017-05-18
JP2017519786A (ja) 2017-07-20
JP6291601B2 (ja) 2018-03-14
WO2016001855A1 (en) 2016-01-07
AU2015283671A1 (en) 2017-02-02
IL249674A0 (en) 2017-02-28
EA201692557A1 (ru) 2017-05-31
KR20170082490A (ko) 2017-07-14
US9944639B2 (en) 2018-04-17

Similar Documents

Publication Publication Date Title
DOP2017000267A (es) Amidas heterocíclicas como inhibidores de quinasa
NI201700096A (es) Derivados de 4h-pirrol[3, 2-c]piridin-4-ona
CU24428B1 (es) Derivados de quinolizinona como inhibidores de pi3k
MX2020011558A (es) Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm.
CL2018001360A1 (es) Inhibidores triazol de acc y usos de los mismos
EA201891211A1 (ru) Ингибиторы cxcr2
CL2017001987A1 (es) Derivados de 1-(het)arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1
CR20150462A (es) Inhibidores de erk y sus usos
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
UY35643A (es) Nuevos compuestos útiles como nematicidas, sus composiciones y métodos de uso
CR20160503A (es) Compuestos de [1,2,4] triazol e imidazol sustituidos, como fungicidas
MX378288B (es) Inhibidores de pirimidina del fgfr4.
UY36175A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
CO2017000064A2 (es) Compuestos de [1,2,4]triazol sustituido
MX2021008376A (es) Cultivo, produccion, procesamiento y uso de cannabis de especialidad.
MX373866B (es) Amidas heterocíclicas como inhibidores de cinasas.
BR112017003414A2 (pt) composições compreendendo caseína e métodos para produzir as mesmas
MX373247B (es) Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y análogos del mismo como inhibidores de atotaxina.
UY36499A (es) Uso de picolinamidas como fungicidas
UY34541A (es) ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?.
UY36737A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
CL2017002856A1 (es) Compuestos de tioéter como inhibidores de la nitrificación
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos
CR20170008A (es) Compuestos de [1,2,4] triazol e imidazol sustituidos